Because DPP-4 inhibitors do not increase (only prolong) the elevation of circulating GLP-1 levels nor induce major weight loss, it is unclear whether they will have a significant beneficial effect on the prevention/treatment of NASH/NAFLD, as opposed to the GLP-1RA which are administered in pharmacologic amounts. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.